These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35267443)

  • 1. Patients Benefit from Liver Transplantation for Hepatocellular Carcinoma beyond Milan Criteria without Harming the Health Care System.
    Gundlach JP; Linecker M; Dobbermann H; Wadle F; Becker T; Braun F
    Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loco-regional hepatocellular carcinoma treatment services as a bridge to liver transplantation.
    Schmitz S; Lurje G; Ulmer F; Andert A; Bruners P; Schulze-Hagen M; Neumann U; Schoening W
    Hepatobiliary Pancreat Dis Int; 2019 Jun; 18(3):228-236. PubMed ID: 30718181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. International study on the outcome of locoregional therapy for liver transplant in hepatocellular carcinoma beyond Milan criteria.
    Degroote H; Piñero F; Costentin C; Notarpaolo A; Boin IF; Boudjema K; Baccaro C; Chagas AL; Bachellier P; Ettorre GM; Poniachik J; Muscari F; Di Benedetto F; Duque SH; Salame E; Cillo U; Gadano A; Vanlemmens C; Fagiuoli S; Rubinstein F; Burra P; Cherqui D; Silva M; Van Vlierberghe H; Duvoux C;
    JHEP Rep; 2021 Oct; 3(5):100331. PubMed ID: 34485882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver transplantation for hepatocellular carcinoma with live donors or extended criteria donors: a propensity score-matched comparison.
    Sotiropoulos GC; Spartalis E; Machairas N; Paul A; Malagó M; Neuhäuser M
    Ann Gastroenterol; 2018; 31(6):722-727. PubMed ID: 30386123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Living Donor Liver Transplantation Outcomes for Hepatocellular Carcinoma Beyond Milan or UCSF Criteria.
    Gunay Y; Guler N; Yaprak O; Dayangac M; Akyildiz M; Altaca G; Yuzer Y; Tokat Y
    Indian J Surg; 2015 Dec; 77(Suppl 3):950-6. PubMed ID: 27011489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver Transplantation Update: 2014.
    Dogan S; Gurakar A
    Euroasian J Hepatogastroenterol; 2015; 5(2):98-106. PubMed ID: 29201702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Outcome-Based Approach to Assign MELD Exception Points for Patients With Hepatocellular Cancer.
    Kensinger CD; Feurer ID; Karp SJ
    Transplantation; 2017 Sep; 101(9):2056-2061. PubMed ID: 28471871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toward optimizing the indications for orthotopic liver transplantation in hepatocellular carcinoma.
    Samuel D; Colombo M; El-Serag H; Sobesky R; Heaton N
    Liver Transpl; 2011 Oct; 17 Suppl 2():S6-13. PubMed ID: 21858912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
    Notarpaolo A; Layese R; Magistri P; Gambato M; Colledan M; Magini G; Miglioresi L; Vitale A; Vennarecci G; Ambrosio CD; Burra P; Di Benedetto F; Fagiuoli S; Colasanti M; Maria Ettorre G; Andreoli A; Cillo U; Laurent A; Katsahian S; Audureau E; Roudot-Thoraval F; Duvoux C
    J Hepatol; 2017 Mar; 66(3):552-559. PubMed ID: 27899297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Simple Measure of Hepatocellular Carcinoma Burden Predicts Tumor Recurrence After Liver Transplantation: The Recurrent Hepatocellular Carcinoma-Initial, Maximum, Last Classification.
    Vutien P; Dodge J; Bambha KM; Nordstrom EM; Gralla J; Campbell K; Levek C; Nydam T; Fix O; Ioannou G; Biggins SW
    Liver Transpl; 2019 Apr; 25(4):559-570. PubMed ID: 30706653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Examinations of Factors Influencing Survival of Liver Transplantation for Hepatocellular Carcinoma: A Single-Center Experience From Budapest.
    Piros L; Fehérvári I; Görög D; Nemes B; Szabó J; Gerlei Z; Végső G; Kóbori L; Máthé Z
    Transplant Proc; 2015 Sep; 47(7):2201-6. PubMed ID: 26361680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient and tumour biology predict survival beyond the Milan criteria in liver transplantation for hepatocellular carcinoma.
    Andreou A; Gül S; Pascher A; Schöning W; Al-Abadi H; Bahra M; Klein F; Denecke T; Strücker B; Puhl G; Pratschke J; Seehofer D
    HPB (Oxford); 2015 Feb; 17(2):168-75. PubMed ID: 25263399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time.
    Decaens T; Roudot-Thoraval F; Hadni-Bresson S; Meyer C; Gugenheim J; Durand F; Bernard PH; Boillot O; Sulpice L; Calmus Y; Hardwigsen J; Ducerf C; Pageaux GP; Dharancy S; Chazouilleres O; Cherqui D; Duvoux C
    Liver Transpl; 2006 Dec; 12(12):1761-9. PubMed ID: 16964590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proposal of a novel MELD exception point system for hepatocellular carcinoma based on tumor characteristics and dynamics.
    Bhat M; Ghali P; Dupont B; Hilzenrat R; Tazari M; Roy A; Chaudhury P; Alvarez F; Carrier M; Bilodeau M
    J Hepatol; 2017 Feb; 66(2):374-381. PubMed ID: 27751840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limited tumour progression beyond Milan criteria while on the waiting list does not result in unacceptable impairment of survival.
    Ferrer-Fàbrega J; Sampson-Dávila J; Forner A; Sapena V; Díaz A; Vilana R; Navasa M; Fondevila C; Miquel R; Ayuso C; García-Valdecasas JC; Bruix J; Reig M; Fuster J
    J Hepatol; 2021 Nov; 75(5):1154-1163. PubMed ID: 34171433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver transplantation for hepatocellular carcinoma: defining the impact of using extended criteria liver allografts.
    Facciuto ME; Singh MK; Katta U; Samaniego S; Sharma J; Rodriguez-Davalos M; Sheiner P; Kim-Schluger L; Wolf DC
    Transplantation; 2011 Aug; 92(4):446-52. PubMed ID: 21694662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor DNA Index and α-Fetoprotein Level Define Outcome following Liver Transplantation for Advanced Hepatocellular Carcinoma.
    Andreou A; Bahra M; Guel S; Struecker B; Sauer IM; Klein F; Pascher A; Pratschke J; Seehofer D
    Eur Surg Res; 2015 Dec; 55(4):302-318. PubMed ID: 26440793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocellular Carcinoma and Liver Transplantation: Changing Patterns and Practices.
    Rich NE; Parikh ND; Singal AG
    Curr Treat Options Gastroenterol; 2017 Jun; 15(2):296-304. PubMed ID: 28425018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver Transplantation for Advanced Hepatocellular Carcinoma after Downstaging Without Up-Front Stage Restrictions.
    Chapman WC; Garcia-Aroz S; Vachharajani N; Fowler K; Saad N; Lin Y; Wellen J; Tan B; Khan AS; Doyle MB
    J Am Coll Surg; 2017 Apr; 224(4):610-621. PubMed ID: 28069527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver Grafts with Major Extended Donor Criteria May Expand the Organ Pool for Patients with Hepatocellular Carcinoma.
    Lozanovski VJ; Kerr LTB; Khajeh E; Ghamarnejad O; Pfeiffenberger J; Hoffmann K; Chang DH; Mieth M; Longerich T; Strobel O; Weiss KH; Büchler MW; Mehrabi A
    J Clin Med; 2019 Oct; 8(10):. PubMed ID: 31618968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.